anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A cosmetic composition with an enhanced carbon dioxide generation rate and viscosity is provided to supply oxygen to skin and to maintain the skin smoothly and vigorously. CONSTITUTION: A cosmetic composition with an enhanced carbon dioxide generation rate and viscosity contains a first agent and a second agent. The first agent contains: 5.0-10.0 wt% of propylene glycol, 3.0-5.0 wt% of sodium carbonate, 1.0-2.0 wt% of ethanol, 0.1-0.5 wt% of phenoxyethanol, 0.5-3.0 wt% of sodium hyaluronate, 0.1-0.5 wt% of ammonium acryloyldimethyl taurate PV copolymers, 2.0-5.0 wt% of cellulose gum as a thickener, 5.0-20.0 wt% of viscous plant extracts, and 60.0-85.0 wt% of water. The second agent contains: powder selected from corn starch, ascorbic acid, dextrin, succinic acid, and citric acid powder. The plant extract contains 0.5-2.0 wt% of a ginseng extract, 0.5-2.0 wt% of a green tea extract, 0.5-2.0 wt% of a Portulaca oleracea L. extract, and 0.5-2.0 wt% of an aloe vera gel extract. The second agent contains: 80.0-95 wt% of purified water; 1.0-3.0 wt% of citric acid, 1.0-5.0 wt% of succinic acid; 2.5-10.0 wt% of vitamin C; and 0.5-2.0 wt% of ammonium acryloyl dimethyl taurate PV copolymers. In the cosmetic composition, the first agent and the second agent are mixed in a ratio of 85.0-95.0 wt%:5.0-15.0 wt%.
Participants randomized to the active group will have an earpiece applied and receive 30 minutes of active tAN therapy immediately prior to the dialysis port placement procedure. When the 30-minute tAN session is complete, the system will be turned off, unplugged, and the earpiece will be removed.
Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
The clinical course of COVID-19 is variable and often unpredictable. To test the hypothesis that disease progression and inflammatory responses associate with alterations in the microbiome and metabolome, we analyzed metagenome, metabolome, cytokine, and transcriptome profiles of repeated samples from hospitalized COVID-19 patients and uninfected controls, and leveraged clinical information and post-hoc confounder analysis. Severe COVID-19 was associated with a depletion of beneficial intestinal microbes, whereas oropharyngeal microbiota disturbance was mainly linked to antibiotic use. COVID-19 severity was also associated with enhanced plasma concentrations of kynurenine and reduced levels of several other tryptophan metabolites, lysophosphatidylcholines, and secondary bile acids. Moreover, reduced concentrations of various tryptophan metabolites were associated with depletion of Faecalibacterium, and tryptophan decrease and kynurenine increase were linked to enhanced production of inflammatory cytokines. Collectively, our study identifies correlated microbiome and metabolome alterations as a potential contributor to inflammatory dysregulation in severe COVID-19.
PROBLEM TO BE SOLVED: To produce a composition that has a little greasy feel and is excellent in emulsion stability when the composition is added to water to be self- emulsified by blending a polar oil and a nonionic surfactant in a specified ratio. SOLUTION: The composition is produced by blending 40-99.5 wt.%, based on the composition, polar oil and 0.5-60 wt.%, based thereon, nonionic surfactant represented by the formula. In the formula, each of R1, R2 and R3 represents independently H or a 16-22C branched fatty acid residue, with the proviso that all of R1, R2 and R3 cannot be H at the same time; a, b and c are each independently an integer of not less than 1; and a+b+c is 10 to 30. As a polar oil, a rapeseed oil is particularly preferable. As a nonionic surfactant, a polyoxyethylene isostearate hardened castor oil is preferable, and one having an HLB of 4-7 is particularly preferable.  The composition is used in a hair cosmetic, a skin cosmetic, a bath agent, a skin external preparation such as an ointment or the like, a detergent composition or the like such as a makeup remover, a face wash, a hair shampoo, a body shampoo or the like.
Itraconazole (6 mg/kg/d; for children less than 15 years old, 200 mg/d for adults) was taken orally for 3-6 months. The specific course of treatment was determined by the research physician according to the recovery of the subjects.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely, to oncology, and can be used in treatment of patients with non-small cell III stage lung carcinoma (NSCLC). For this purpose, first laboratory estimation of initial cortisol production is performed and in case of its normal indices carried out is pre-medication that includes intramuscular introduction of dexamethasone in accordance with the scheme: 20 mg 13 hours, 10 mg 7 hours and 10 mg 2 hours before carrying out chemical therapy with taxanes. Cortisol level is determined repeatedly immediately before infusion of taxanes and after operation. In case if level of peak cortisol secretion in post-operation period in early morning hours drops lower than 300 nmole/l drug correction with glucocorticosteroids is carried out additionally until normalisation of indices. ^ EFFECT: method allows to reduce number of post-operation complications in said category of patients due to preventive drug correction of possible adrenal insufficiency with simultaneous prevention of hypersensitivity responses to introduction of taxanes. ^ 2 ex
Approximately 2.1 million patients in the United States acquire infections during medical care every year. For example, 9%-30% patients who undergo surgery acquire nosocomial infections, which increase mortality and morbidity over that expected normally expected and increase the cost of care by several billion dollars. Studies have shown that controlling high blood glucose levels dramatically improves the recovery of critically ill patients after surgery, most notably decreasing the risk of infection. The advantage of strict glycemic control in the critically ill patient is now well accepted, and the Institute for Healthcare Improvement and Surviving Sepsis Campaign set glycemic control as part of the post-operative sepsis management bundle.

Few studies have investigated the role of strict glycemic control during surgery itself. Liver transplantation is a good model for studying glucose control as hyperglycemia almost always occurs and the incidence of infection is higher than with other surgical procedures. We performed a retrospective review of 184 consecutive adult liver recipients in which intra-operative blood glucose levels were measured and treated with insulin. Recipients with strict glycemic control were compared to those with poor control for differences in donor and recipient demographics, intra-operative blood glucose concentrations, intra-operative insulin administered, immunosuppression, post-operative complications, and mortality. Poor glycemic control was associated with a significantly increased rate of infection during the first 30 days post-operatively (48% vs. 33%, P=0.05) and 1-year mortality was significantly increased for those recipients with poor intra-operative glucose control (21.9% vs. 8.8%; P = 0.05). These data along with the post-operative studies, suggest that the post-transplant mortality rate may potentially be decreased by nearly 50% at 1 year and underscore the need for this to be confirmed in a prospective trial.

The goal of this study is to prospectively evaluate the outcomes of liver transplant recipients to either strict glucose control (goal of 80-110 mg/dl) or the current standard of care (goal of between 180 and 200 mg/dl). The specific aim of this study is to determine if strict intra-operative blood glucose control, improves 1-year recipient survival and decreases surgical complications, including infections, following liver transplantation. The rates of infection at 30 days after surgery and health at one year post- surgery will be compared. The frequency of other common post-operation complications will also be studied. The proposed study has the potential to have an impact on the intra-operative management of all liver transplant recipients.
Cerebrospinal fluid (CSF) is a body fluid that can be used for the diagnosis of various diseases. However, CSF collection requires an invasive and painful procedure called a lumbar puncture (LP). This procedure is applied to any patient with a known risk of central nervous system (CNS) damage or neurodegenerative disease, regardless of their age range. Hence, this can be a very painful procedure, especially in infants and elderly patients. On the other hand, the detection of disease biomarkers in CSF makes diagnoses as accurate as possible. This review aims to explore novel electrochemical biosensing platforms that have impacted biomedical science. Biosensors have emerged as techniques to accelerate the detection of known biomarkers in body fluids such as CSF. Biosensors can be designed and modified in various ways and shapes according to their ultimate applications to detect and quantify biomarkers of interest. This process can also significantly influence the detection and diagnosis of CSF. Hence, it is important to understand the role of this technology in the rapidly progressing field of biomedical science.
Individuals will participate in 3 sessions of Self Determined Intensity Interval training per week for 4 weeks, using a stationary bike at an intensity whereby their Ratings of Perceived exertion (RPE) is challenging. RPE will be measured using a Borg's 6-20 scale. (44). The cycling protocol will include a 3-minute warm-up, five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery. and a 2-minute cool-down. The RPE will be acquired by asking the participant to provide their rating at the end of the last interval.
The present invention relates to a composite composition for preventing and alleviating hair loss containing a medicinal herb extract consisting of Artemisiae Annuae Herba, Siberian chrysanthemum, dried young stems of artemisia, dried Artemisia capillaris Thunb, Sophorae Fructus, dried Cirsium japonicum var. maackii (Maxim.) Matsum, and elecampane. To this end, the composite composition of the present invention is produced by the following steps: mixing purified water containing 1-5% content of 1,3-butylene glycol, Artemisiae Annuae Herba, Siberian chrysanthemum, dried young stems of artemisia, dried Artemisia capillaris Thunb, Sophorae Fructus, dried Cirsium japonicum var. maackii (Maxim.) Matsum, and elecampane at the weight ratio of 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25: and extracting and concentrating the same thereafter.
PURPOSE: To provide an anticarcinogeous activator contg. lycopene as an active component and having a cancer cell proliferation inhibitive effect. CONSTITUTION: The lycopene expressed by the formula is incorporated as the effective component into this activator. The lycopene is natural extract and more particularly the extract of tomatoes. The lycopene along or is compounded with a medicinally active material, carrier, adjuvant, additives, etc., and is subjected to pharmaceutical manufacturing in the form of injection, oral and rectal medication. The activator prohibits the cell proliferation of the mammary cancer, endometrial carcinoma, prostatic cancer, ovarian cancer, melanoma, bladder cancer, pancreatic cancer, gastric cancer, hepatic cancer, leukemia, blastocytoma, neuroblastocytoma, other brain tumors and head cancers. The lycopene is substantially insoluble in water and is included in algae, other fruits and vegetables as well.
Same procedure as experimental . The only difference between the two groups regarding the intervention will be the percentage of blood flow restriction cuff pressure. In the sham BFR group, as much pressure as 2 fingers can penetrate the cuff will be automatically applied via MADUP®, where based on the literature seems not to promote adaptations related to the use of the method.
The invention relates to the medical technical field of repairing wounds, which can be used for repairing wounds, particularly for healing deep burn wounds. The invention provides mesenchymal stem cell suspension which contains human epidermal growth factor and bovine basophilic fibroblast growth factor. The mesenchymal stem cell provides the sources for human marrows or embryo. When in use, the stem cell suspension is directly injected or smeared on wounds which have been removed necrotic tissues. Animal experiments show that the stem cell suspension can obviously repair deep burn wounds; besides, the new skin does not tend to generate blister or ulceration. The stem cell suspension of the invention is simple in preparation and conveniently for use, obviously repairing the deep burn wounds, thus effectively controlling the hyperplasia of anaphase keloid.
A 10-year-old American Shorthair cat presented with anorexia and jaundice, and echogenic evaluation revealed diffuse thickening of the common bile duct (CBD) wall. An exploratory laparotomy was conducted, the lesion was evaluated as difficult to remove, and the cat was euthanized and autopsied. Histologically, round neoplastic cells proliferated in the mucosa of the CBD and infiltrated the hepatic lobe, pancreas, and duodenum. Immunohistochemistry revealed that the neoplastic cells were positive for cytoplasmic-CD3 and granzyme B, and TCR-gamma clonal rearrangement was detected. Based on these findings, the neoplasia was diagnosed as a primary CBD lymphoma originating from cytotoxic T or natural killer cells. To the best of our knowledge, this is the first reported case of feline primary CBD lymphoma. Although rare, lymphoma of the CBD should be considered in cats with jaundice and thickening of the CBD.
PURPOSE:To obtain a obtain steroid therapeutic agent for dermatosis having high safety, comprising an extract of tea, especially oolong tea as an active ingredient. CONSTITUTION:Leaves of oolong tea are naturally dried to remove 30-50% of water and stirred for several hours. Then the tea leaves are roasted by a pot and redried while rubbing. The prepared oolong tea leaves are extracted with 10-20 times as much as deionized water at 50-100 deg.C for 5-30 minutes, the extracted solution is adjusted to about pH5.0 with ascorbic acid and concentrated under reduced pressure at 40-60 deg.C to give a concentrated solution having 10-20 Brix or further dried to give dried powder. The dried powder is dissolved in warm water for bath as it is for drinking with warm water or is properly mixed with an additive for medicine and pharmaceutically manufactured. The prepared steroid therapeutic agent for dermatosis shows thermo-keeping effect, moisture retaining effect, antipruritic effect, normalizing effect on acanthosis and a lichen state and anti-inflammatory effect and is also useful as a therapeutic agent for atopic dermatitis.
The present invention relates to a modified IgE Fc receptor with high sialic acid content and a pharmaceutical composition comprising the same. A polypeptide dimer with high sialic acid content according to the present invention not only has excellent safety and persistence in the body compared to a conventionally used anti-IgE antibody, but also strongly binds to IgE, and thus has an advantage of extending the administration interval. In addition, the polypeptide dimer with high sialic acid content according to the present invention is a substance with a single target of IgE and does not bind to an Fc gamma receptor, unlike the conventional anti-IgE antibody to which Fc of IgG1 is applied. As a result, the release of a mediator due to a bond with an Fc gamma receptor on the surface of a mast cell can be inhibited, and side effects such as anaphylaxis and the like, which can be induced by the binding of IgG1 to Fc gamma receptor III of the mast cell, can be minimized. In addition, the polypeptide dimer with high sialic acid content can maintain a high blood concentration even when administered subcutaneously. Therefore, the polypeptide dimer with high sialic acid content according to the present invention can effectively be used to prevent or treat allergic diseases.
Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
The invention provides a cinnabar water-grinding device based on cams. The cinnabar water-grinding device based on the cams comprises a press-grinding block, a base, the cams and power shafts. The press-grinding block is in a cone shape. A conical pit matched with the press-grinding block in shape is formed in the base, and the diameter of the conical pit in the base is 2-10 cm larger than that of the cone of the press-grinding block. The cams are perpendicularly arranged at the top of the press-grinding block and driven by the power shafts which are arranged horizontally, and the power shafts are arranged in different directions. According to the cinnabar water-grinding device based on the cams, through the structure including the press-grinding block, the base and the cams, and the conical matching structure, water grinding of cinnabar can be well completed; and the cinnabar water-grinding device is extremely low in cost, durable, simple in structure and easy to maintain, and the labor cost can be effectively reduced.
BACKGROUND: Understanding the association of acute pain intensity and opioid consumption after cardiac surgery with chronic postsurgical pain (CPSP) can facilitate implementation of personalized prevention measures to improve outcomes. The objectives were to (1) examine acute pain intensity and daily mg morphine equivalent dose (MME/day) trajectories after cardiac surgery, (2) identify factors associated with pain intensity and opioid consumption trajectories, and (3) assess whether pain intensity and opioid consumption trajectories are risk factors for CPSP.
METHODS: Prospective observational cohort study design conducted between August 2012 and June 2020 with 1-year follow-up. A total of 1115 adults undergoing cardiac surgery were recruited from the preoperative clinic. Of the 959 participants included in the analyses, 573 completed the 1-year follow-up. Main outcomes were pain intensity scores and MME/day consumption over the first 6 postoperative days (PODs) analyzed using latent growth mixture modeling (GMM). Secondary outcome was 12-month CPSP status.
RESULTS: Participants were mostly male (76%), with a mean age of 61 ± 13 years. Three distinct linear acute postoperative pain intensity trajectories were identified: "initially moderate pain intensity remaining moderate" (n = 62), "initially mild pain intensity remaining mild" (n = 221), and "initially moderate pain intensity decreasing to mild" (n = 251). Age, sex, emotional distress in response to bodily sensations, and sensitivity to pain traumatization were significantly associated with pain intensity trajectories. Three distinct opioid consumption trajectories were identified on the log MME/day: "initially high level of MME/day gradually decreasing" (n = 89), "initially low level of MME/day remaining low" (n = 108), and "initially moderate level of MME/day decreasing to low" (n = 329). Age and emotional distress in response to bodily sensations were associated with trajectory membership. Individuals in the "initially mild pain intensity remaining mild" trajectory were less likely than those in the "initially moderate pain intensity remaining moderate" trajectory to report CPSP (odds ratio [95% confidence interval, CI], 0.23 [0.06-0.88]). No significant associations were observed between opioid consumption trajectory membership and CPSP status (odds ratio [95% CI], 0.84 [0.28-2.54] and 0.95 [0.22-4.13]).
CONCLUSIONS: Those with moderate pain intensity right after surgery are more likely to develop CPSP suggesting that those patients should be flagged early on in their postoperative recovery to attempt to alter their trajectory and prevent CPSP. Emotional distress in response to bodily sensations is the only consistent modifiable factor associated with both pain and opioid trajectories.
In vitrostudies and in vivopharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2-adrenergic receptors compared with isoproterenol. While it is recognized that beta 2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta 2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS). 

The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.

Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- O-methyl transferase. 

Pharmacokinetics

Studies in asthmatic patients have shown that less than 20% of a single albuterol dose was absorbed following either intermittent positive-pressure breathing (IPPB) or nebulizer administration; the remaining amount was recovered from the nebulizer and apparatus and expired air. Most of the absorbed dose was recovered in the urine 24 hours after drug administration. Following a 3 mg dose of nebulized albuterol, the maximum albuterol plasma level at 0.5 hour was 2.1 ng/mL (range 1.4 to 3.2 ng/mL). There was a significant dose-related response in FEV 1and peak flow rate. It has been demonstrated that following oral administration of 4 mg of albuterol, the elimination half-life was 5 to 6 hours.